Abstract
Based on one-year experience with faricimab in a large retina-only practice, our study identified a 1.9% rate of serious ocular adverse events and a similarly low rate of intraocular inflammation that was comparable to clinical trials.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
